Clinical Trial Update: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Ianalumab versus placebo in addition to first-line corticosteroids for primary immune thrombocytopenia is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 3 | Status: ACTIVE_NOT_RECRUITING